Similar articles

• [Numerous indications in cardiology. Beta receptor blockers can never be overlooked].

  [No authors listed] [No authors listed] MMW Fortschr Med. 2005 May 5;147(18):57. MMW Fortschr Med. 2005. PMID: 15934594 German. No abstract available.
• Nonselective versus selective beta-blockers in the management of chronic heart failure: clinical implications of the carvedilol or Metoprolol European Trial.

  Greenberg B. Greenberg B. Rev Cardiovasc Med. 2004;5 Suppl 1:S10-7. Rev Cardiovasc Med. 2004. PMID: 15184835 Review.
• What resting heart rate should one aim for when treating patients with heart failure with a beta-blocker? Experiences from the Metoprolol Controlled Release/Extended Release Randomized Intervention Trial in Chronic Heart Failure (MERIT-HF).

  Gullestad L, Wikstrand J, Deedwania P, Hjalmarson A, Egstrup K, Elkayam U, Gottlieb S, Rashkow A, Wedel H, Bermann G, Kjekshus J; MERIT-HF Study Group. Gullestad L, et al. J Am Coll Cardiol. 2005 Jan 18;45(2):252-9. doi: 10.1016/j.jacc.2004.10.032. J Am Coll Cardiol. 2005. PMID: 15653024 Clinical Trial.
• COMET: a proposed mechanism of action to explain the results and concerns about dose.

  Wikstrand J, Fagerberg B, Goldstein S, Kjekshus J, Wedel H. Wikstrand J, et al. Lancet. 2003 Sep 27;362(9389):1076-7; author reply 1077-8. doi: 10.1016/S0140-6736(03)14421-2. Lancet. 2003. PMID: 14522542 No abstract available.
• [Use of metoprolol CR/ZOK in the cardiological practice].

  Podzolkov VI, Samoĭlenko VV, Osadchiĭ KK, Strizhakov LA. Podzolkov VI, et al. Ter Arkh. 2000;72(9):78-80. Ter Arkh. 2000. PMID: 11076427 Review. Russian. No abstract available.